How many stocks are there of Glaukos?
The current number of stocks of Glaukos is 48.43 M undefined.
Glaukos Stocks 2024
Glaukos Stocks
48.43 M
Ticker
GKOS
ISIN
US3773221029
WKN
A14VCK
In 2024, Glaukos had 48.43 M outstanding stocks, a 0% change from the 48.43 M stocks in the previous year.
The Glaukos Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 48.43 |
| 2028e | 48.43 |
| 2027e | 48.43 |
| 2026e | 48.43 |
| 2025e | 48.43 |
| 2024e | 48.43 |
| 2023 | 48.43 |
| 2022 | 47.4 |
| 2021 | 46.4 |
| 2020 | 44.5 |
| 2019 | 41.1 |
| 2018 | 35.3 |
| 2017 | 34.4 |
| 2016 | 36.5 |
| 2015 | 17.5 |
| 2014 | 29.7 |
| 2013 | 29.7 |
| 2012 | 29.7 |
Glaukos shares outstanding US3773221029 · A14VCK
The number of shares was Glaukos in 2023 — This indicates how many shares 48.433 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Glaukos earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Glaukos's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Glaukos’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Glaukos's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2012 | 29.7 M Aktien |
| 2013 | 29.7 M Aktien |
| 2014 | 29.7 M Aktien |
| 2015 | 17.5 M Aktien |
| 2016 | 36.5 M Aktien |
| 2017 | 34.4 M Aktien |
| 2018 | 35.3 M Aktien |
| 2019 | 41.1 M Aktien |
| 2020 | 44.5 M Aktien |
| 2021 | 46.4 M Aktien |
| 2022 | 47.4 M Aktien |
| 2023 | 48.43 M Aktien |
| 2024e | 48.43 M Aktien |
| 2025e | 48.43 M Aktien |
| 2026e | 48.43 M Aktien |
| 2027e | 48.43 M Aktien |
| 2028e | 48.43 M Aktien |
| 2029e | 48.43 M Aktien |
Glaukos Aktienanalyse
What does Glaukos do?
Glaukos Corp is a medical technology company specializing in developing devices and therapies for treating eye diseases. It was founded in 1998 by employees of the ophthalmology center at the University of California San Francisco. The company focuses on utilizing new technologies and therapies to improve the vision quality of patients. They have developed innovative products for diagnosing and treating various eye conditions, including glaucoma. Their core business involves manufacturing and distributing medical devices for glaucoma treatment, such as the iStent implant. They have also partnered with other institutions to advance research and development in the field of ophthalmology. In 2018, Glaukos Corp acquired the German manufacturer Markt II Medical, expanding their product offerings for a wider range of eye diseases. In summary, Glaukos Corp is an innovative medical technology company that aims to enhance patients' vision quality while minimizing the risks of eye surgery. Glaukos ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Glaukos's Shares Outstanding
Glaukos's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Glaukos’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Glaukos’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Glaukos’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Glaukos stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Glaukos are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Glaukos evolved in recent years?
The number of shares of Glaukos has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Glaukos as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Glaukos?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Glaukos pay?
Over the past 12 months, Glaukos paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Glaukos is expected to pay a dividend of 0 USD.
What is the dividend yield of Glaukos?
The current dividend yield of Glaukos is .
When does Glaukos pay dividends?
Glaukos pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Glaukos?
Glaukos paid dividends every year for the past 0 years.
What is the dividend of Glaukos?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Glaukos located?
Glaukos is assigned to the 'Health' sector.
Wann musste ich die Aktien von Glaukos kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Glaukos from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did Glaukos pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of Glaukos in the year 2023?
In the year 2023, Glaukos distributed 0 USD as dividends.
In which currency does Glaukos pay out the dividend?
The dividends of Glaukos are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Glaukos
Our stock analysis for Glaukos Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Glaukos Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
